19:58 , Jan 19, 2018 |  BC Week In Review  |  Company News

Capricor and Cedars-Sinai expand cardiosphere deal

Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights to develop and commercialize cardiosphere-derived cells (CDC) and CDC-derived extracellular vesicles, including exosomes, by adding seven new patent applications...
20:57 , May 12, 2017 |  BC Extra  |  Clinical News

Capricor stem cell therapy misses heart repair endpoint

Capricor Therapeutics Inc. (NASDAQ:CAPR) sank $1.89 (62%) to $1.16 in afternoon trading on Friday after it said a six-month interim futility analysis showed intracoronary CAP-1002 is unlikely to meet the primary endpoint compared to placebo...